Response to Comments: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

This document is a response-to-comments notice related to MolDX LCD L39583 on molecular biomarker testing for risk stratification of cutaneous squamous cell carcinoma and does not itself define coverage criteria. It records the comment period (06/08/2023–07/22/2023), the notice period start (07/04/2024), and the LCD effective date (08/18/2024). Manual review of the final LCD L39583 is required to extract actionable coverage, limitation, documentation, and frequency criteria for the test.